Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART).:a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

Autor: Connick, P, De Angelis, F, Parker, Ra, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, Sh, Giovannoni, G, Gandini Wheeler-Kingshott CA, Hawkins, C, Sharrack, B, Bastow, R, Weir, Cj, Stallard, N, Chandran, S, Chataway, J, UK Multiple Sclerosis Society Clinical Trials, Network.

Publikováno v: Connick, P, De Angelis, F, Parker, R, Plantone, D, Doshi, A, John, N, Stutters, J, MacManus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M & Cranswick, G & Weir, C 2018, ' Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART). a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis ', BMJ Open . https://doi.org/10.1136/bmjopen-2018-021944
Connick, P, De Angelis, F, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-Kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & Chataway, J 2018, ' Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART) : A multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis ', BMJ Open, vol. 8, no. 8, e021944 . https://doi.org/10.1136/bmjopen-2018-021944
BMJ Open, 8(8):e021944. BMJ Publishing Group
BMJ Open

IntroductionThe major unmet need in multiple sclerosis (MS) is for neuroprotective therapies that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical Trials Network (CTN) was initiated in 2007 with the purpose of de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66923089bdc106d1eba9998777926e8f
https://hdl.handle.net/20.500.11820/c9a0ef03-ec4e-4816-90f6-cbb523836bff